|
1
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fizazi K, Scher HI, Molina A, Logothetis
CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F,
et al: Abiraterone acetate for treatment of metastic
castration-resistant prostate cancer: Final overall survival
analysis of the COU-AA-301 randomized, double-blind,
placebo-controlled phase 3 study. Lancet Oncol. 13:983–992. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harland S, Staffurth J, Molina A, Hao Y,
Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T,
et al: Effect of abiraterone acetate treatment on the quality of
life of patients with metastatic castration-resistant prostate
cancer after failure of docetaxel chemotherapy. Eur J Cancer.
49:3648–3657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Francini E, Petrioli R and Roveiello G: No
clear evidence of a sequential therapy regimen with abiraterone
acetate and enzalutamide. Expert Rev Anticancer Ther. 14:1135–1140.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scher HI, Morris MJ, Basch E and Heller G:
End points and outcomes in castration-resistant prostate cancer:
From clinical trials to clinical practice. J Clin Oncol.
29:3695–3704. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sternberg CN, Molina A, North S,
Mainwaring P, Fizazi K, Hao Y, Rothman M, Gagnon DD, Kheoh T, Haqq
CM, et al: Effect of abiraterone acetate on fatigue in patients
with metastatic castration-resistant prostate cancer after
docetaxel chemotherapy. Ann Oncol. 24:1017–1025. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naito S, Tsukamoto T, Koga H, Harabayashi
T, Sumiyoshi Y, Hoshi S and Akaza H: Docetaxel plus prednisolone
for the treatment of metastatic hormone-refractory prostate cancer:
A multicenter phase II trial in Japan. Jpn J Clin Oncol.
38:365–372. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horgan AM, Seruga B, Pond GR, Alibhai SM,
Amir E, De Wit R, Eisenberger MA and Tannock IF: Tolerability and
efficacy of docetaxel in older men with metastatic
castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J
Geriatr Oncol. 5:119–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Italiano A, Ortholan C, Oudard S, Pouessel
D, Gravis G, Beuzeboc P, Bompas E, Fléchon A, Joly F, Ferrero JM
and Fizazi K: Docetaxel-based chemotherapy in elderly petients (age
75 and older) with castration-resistant prostate cancer. Eur Urol.
55:1368–1375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part II:
Treatment of advanced, relapsing, and castration-resistant prostate
cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basch E, Loblaw DA, Oliver TK, Carducci M,
Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, et
al: Systemic therapy in men with metastatic castration-resistant
prostate cancer: American society of clinical oncology and cancer
care ontario clinical practice guideline. J Clin Oncol.
32:3463–3448. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rathkopf DE, Smith MR, de Bono JS,
Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF,
Mainwaring P, Hainsworth JD, et al: Update interim efficacy
analysis and long-term safety of abiraterone acetate in metastatic
castration-resistant prostate cancer patients without prior
chemotherapy (COU-AA-302). Eur Urol. 66:815–825. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beer TM, Armstrong AJ, Rathkopf DE, Loriot
Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J,
Chowdhury S, et al: PREVAIL Investigators: Enzalutamide in
metastatic prostate cancer before chemotherapy. N Engl J Med.
371:424–433. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Houédé N, Beuzeboc P, Gourgou S, Tosi D,
Moise L, Gravis G, Delva R, Fléchon A, Latorzeff I, Ferrero JM, et
al: Abiraterone acetate in patients with metastatic
castration-resistant prostate cancer: Long term outcome of the
temporary authorization for use programme in France. BMC Cancer.
15:2222015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Soest RJ, de Morrée ES, Shen L,
Tannock IF, Eisenberger MA and de Wit R: Initial biopsy gleason
score as a predictive marker for survival benefit in patients with
castration-resistant prostate cancer treated with docetaxel: Data
from the TAX327 study. Eur Urol. 66:330–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kamiya N, Suzuki H, Ueda T, Sato N,
Nakatsu H, Mikami K, Sato N, Nomura K, Akakura K, Okano T, et al:
Clinical outcomes by relative docetaxel dose and dose intensity as
chemotherapy for Japanese patients with castration-resistant
prostate cancer: A retrospective multi-institutional collaborative
study. Int J Clin Oncol. 19:157–164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kita Y, Shimizu Y, Inoue T, Kamba T,
Yoshimura K and Ogawa O: Reduced-dose docetaxel for
castration-resistant prostate cancer has no inferior impact on
overall survival in Japanese patients. Int J Clin Oncol.
18:718–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakai Y, Nishimura K, Nakayama M, Uemura
M, Takayama H, Nonomura N and Tsujimura A: Osaka CRPC Clinical
Study Collaboration: Weekly, low-dose docetaxel combined with
estramustine for Japanese castration-resistant prostate cancer: Its
efficacy and safety profile compared with tri-weekly standard-dose
treatment. Int J Clin Oncol. 19:165–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimabukuro T, Sakano S, Matsuda K,
Kamiryo Y, Yamamoto N, Kaneda Y, Nasu T, Baba Y, Suga A, Yamamoto
M, et al: Can docetaxel therapy improve overall survival from
primary therapy compared with androgen-deprivation therapy alone in
Japanese patients with castration-resistant prostate cancer? A
multi-institutional cooperative study. Int J Clin Oncol. 18:62–67.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyake H, Sakai I, Terakawa T, Harada K
and Fujisawa M: Oncological outcome of docetaxel-based chemotherapy
for Japanese men with metastatic castration-resistant prostate
cancer. Urol Oncol. 31:733–738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakagami Y, Ohori M, Sakamoto N, Koga S,
Hamada R, Hatano T and Tachibana M: Safety and efficacy of
docetaxel, estramustine phosphate and hydrocortisone in
hormone-refractory prostate cancer patients. Int J Urol.
17:629–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miura N, Numata K, Kusuhara Y, Shirato A,
Hashine K and Sumiyoshi Y: Docetaxel-prednisolone combination
therapy for Japanese patients with hormone-refractory prostate
cancer: A single institution experience. Jpn J Clin Oncol.
40:1092–1098. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Armstrong AJ, Garrett-Mayer E, de Wit R,
Tannock I and Eisenberger M: Prediction of survival following
first-line chemotherapy in men with castration-resistant metastatic
prostate cancer. Clin Cancer Res. 16:203–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
D'Amico AV, Cote K, Loffredo M, Renshaw AA
and Schultz D: Determinations of prostate cancer-specific survival
after radiation therapy for patients with clinically localized
prostate cancer. J Clin Oncol. 20:4567–4573. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Crawford ED, Bennett CL, Andriole GL,
Garnick MB and Petrylak DP: The utility of prostate-specific
antigen in the management of advanced prostate cancer. BJU Int.
112:548–560. 2013. View Article : Google Scholar : PubMed/NCBI
|
